As was previously announced, Academy Medical will be reselling SofPulse® medical devices to the
The partnership is expected to benefit military personnel, veterans and their families who are among the largest user groups of these healthcare delivery systems.
SofPulse® Included in VHA Procurement System
With the launch of SofPulse® into the Federal marketplace Endonovo, along with Academy Medical, have the potential to significantly improve access to SofPulse® to military personnel and veterans. The addition of SofPulse® into the VHA procurement system offers Endonovo the ability to sell into the largest healthcare Integrated Delivery Network (IDN) in the country. The procurement system is designed to streamline logistics and supply management for medical and surgical items providing veterans and military healthcare facilities with easier access to the products they need.
In making the announcement,
Academy Medical is a reliable provider of medical and surgical items to the Federal marketplace with over 45,000 products from more than 30 supplier partners.
“The partnership between Academy Medical and Endonovo provides veterans an opportunity to benefit from the device’s unique PEMF technology,” according to CEO,
The sales launch with Academy Medical reaffirms that both companies have joined forces to improve healthcare solutions for military personnel and veterans. The partnership aims to provide better access to medical and surgical supplies, along with telehealth solutions, with the goal of making a tangible impact on the lives of those who have served their country. The VHA, which serves 9 million enrolled veterans annually through its 1,298 healthcare facilities, including 171 medical centers and 1,113 outpatient sites, will benefit from the inclusion of SofPulse® medical devices in the VHA procurement system.
The proven postoperative pain and edema reduction solution will be readily available to military personnel and veterans. Together Endonovo and Academy Medical anticipates significant advancements in healthcare for those who have bravely served their country.
SofPulse® Postoperative Pain and Edema Relief
Endonovo's SofPulse® PEMF devices provide a clinically proven and FDA-cleared alternative to opioid pain management, specifically for reducing postoperative pain and edema. With the launch of sales initiatives surrounding the partnership, Academy Medical aims to expand the distribution of SofPulse® devices, benefiting military personnel and veterans with improved recovery times and reduced opioid use. Endonovo's commercialization of the SofPulse® line is led by Weisberg, a seasoned expert in revenue growth for medical device companies, positioning the company for success.
Growth Opportunities
Endonovo's mission to revolutionize medical solutions for patients with a range of conditions includes advancing its patented technology for Central Nervous System (CNS) and Traumatic Brain Injury (TBI). The commencement of the
About
About Academy Medical, Inc.
Academy Medical is a premier Service-Disabled Veteran-Owned Small Business and distributor of medical-surgical equipment and supplies to the
Academy Medical is headquartered in
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate", "believe", "plan", "estimate", "expect", "intend" and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the
Investor Relations Contact:
(800) 701-1223 Ext. 108
sbarnes@endonovo.com
www.endonovo.com
Media Contact:
(310) 804-7037
greg@gregmcandrews.com
Source:
2023 GlobeNewswire, Inc., source